The T-Cell Immunotherapy market is expected to exceed more than US$ 107 Billion by 2028 at a CAGR of 16% in the given forecast period.
Growing adoption of advanced cancer therapeutic options coupled with rising cancer incidence has been one of the primary growth stimulants for the market. Healthcare providers are focusing on improving cancer therapeutic facilities and reduction in reoccurrence rate of tumor post chemotherapy. CAR T-cell therapies are the most researched type of therapy as they have shown exceptional results during clinical trials. The market for such T-cell Immunotherapies is forecasted to grow at an exponential rate owing to the high venture capitalist investments and increasing research related activities in this field.
T-cell therapies (specifically CAR-T, TCR and TIL therapies) have emerged as a promising option owing to their capability to eradicate tumor cells from the body with minimal treatment-related side effects. These adoptive T-cell therapies (ACT) are based on the principle of harnessing the innate potential of the immune system to target and destroy diseased cells.
The global T-Cell Immunotherapy market is segregated on the basis of Application as Stomach Cancer, Lung Cancer, Colorectal Cancer, Esophagus Cancer, Pancreatic Cancer, and Others. Based on Type the global T-Cell Immunotherapy market is segmented in CAR-T, TCR, and TIL Therapies.
The global T-Cell Immunotherapy market report provides geographic analysis covering regions, such as North America, Europe, Asia-Pacific, and Rest of the World. The T-Cell Immunotherapy market for each region is further segmented for major countries including the U.S., Canada, Germany, the U.K., France, Italy, China, India, Japan, Brazil, South Africa, and others.
Competitive Rivalry
Adaptimmune, Altor Bioscience Corporation, Cellectis, Juno Therapeutics, Kite Pharma, Novartis, Takara Bio, Unum Therapeutics and others are among the major players in the global T-Cell Immunotherapy market. The companies are involved in several growth and expansion strategies to gain a competitive advantage. Industry participants also follow value chain integration with business operations in multiple stages of the value chain.
The T-Cell Immunotherapy Market has been segmented as below:
T-Cell Immunotherapy Market, By Application
T-Cell Immunotherapy Market, By Type
T-Cell Immunotherapy Market, By Region
T-Cell Immunotherapy Market, By Company
The report covers:
Report Scope:
The global T-Cell Immunotherapy market report scope includes detailed study covering underlying factors influencing the industry trends.
The report covers analysis on regional and country level market dynamics. The scope also covers competitive overview providing company market shares along with company profiles for major revenue contributing companies.
The report scope includes detailed competitive outlook covering market shares and profiles key participants in the global T-Cell Immunotherapy market share. Major industry players with significant revenue share include Adaptimmune, Altor Bioscience Corporation, Cellectis, Juno Therapeutics, Kite Pharma, Novartis, Takara Bio, Unum Therapeutics and others.
Reasons to Buy this Report:
Customization
Customized report as per the requirement can be offered with appropriate recommendations
Below are our new reports:
1. Introduction
1.1 Key Insights
1.2 Report Overview
1.3 Markets Covered
1.4 Stakeholders
2. Research Methodology
2.1 Research Scope
2.2 Market Research Process
2.3 Research Data Analysis
2.4.1 Secondary Research
2.4.2 Primary Research
2.4.3 Models for Estimation
2.5 Market Size Estimation
2.5.1 Bottom-Up Approach – Segmental Market Analysis
2.5.2 Top-Down Approach – Parent Market Analysis
3. Executive Summary
4. Market Overview
4.1 Introduction
4.2.1 Drivers
4.2.2 Restraints
4.2.3 Opportunities
4.2.4 Challenges
4.2 Porter’s Five Force Analysis
5. T-Cell Immunotherapy Market, By Application
5.1 Introduction
5.2 Stomach Cancer
5.2.1 Market Overview
5.2.2 Market Size and Forecast
5.3 Lung Cancer
5.3.1 Market Overview
5.3.2 Market Size and Forecast
5.4 Colorectal Cancer
5.4.1 Market Overview
5.4.2 Market Size and Forecast
5.5 Esophagus Cancer
5.5.1 Market Overview
5.5.2 Market Size and Forecast
5.6 Pancreatic Cancer
5.6.1 Market Overview
5.6.2 Market Size and Forecast
5.7 Others
5.7.1 Market Overview
5.7.2 Market Size and Forecast
6. T-Cell Immunotherapy Market, By Type
6.1 Introduction
6.2 CAR-T
6.2.1 Market Overview
6.2.2 Market Size and Forecast
6.3 TCR
6.3.1 Market Overview
6.3.2 Market Size and Forecast
6.4 TIL Therapies
6.4.1 Market Overview
6.4.2 Market Size and Forecast
7. T-Cell Immunotherapy Market, By Geography
7.1 Introduction
7.2 North America
7.2.1 North America T-Cell Immunotherapy, By Application
7.2.2 North America T-Cell Immunotherapy, By Type
7.3 Europe
7.3.1 Europe T-Cell Immunotherapy, By Application
7.3.2 Europe T-Cell Immunotherapy, By Type
7.4 Asia-Pacific
7.4.1 Asia-Pacific T-Cell Immunotherapy, By Application
7.4.2 Asia-Pacific T-Cell Immunotherapy, By Type
7.5 Rest of the World
7.5.1 Rest of the World T-Cell Immunotherapy, By Application
7.5.2 Rest of the World T-Cell Immunotherapy, By Type
8. Competitive Insights
8.1 Key Insights
8.2 Company Market Share Analysis
8.3 Strategic Outlook
8.3.1 Mergers & Acquisitions
8.3.2 New Product Development
8.3.3 Portfolio/Production Capacity Expansions
8.3.4 Joint Ventures, Collaborations, Partnerships & Agreements
8.3.5 Others
9. Company Profiles
9.1 Adaptimmune
9.1.1 Company Overview
9.1.2 Product/Service Landscape
9.1.3 Financial Overview
9.1.4 Recent Developments
9.2 Altor Bioscience Corporation
9.2.1 Company Overview
9.2.2 Product/Service Landscape
9.2.3 Financial Overview
9.2.4 Recent Developments
9.3 Cellectis
9.3.1 Company Overview
9.3.2 Product/Service Landscape
9.3.3 Financial Overview
9.3.4 Recent Developments
9.4 Juno Therapeutics
9.4.1 Company Overview
9.4.2 Product/Service Landscape
9.4.3 Financial Overview
9.4.4 Recent Developments
9.5 Kite Pharma
9.5.1 Company Overview
9.5.2 Product/Service Landscape
9.5.3 Financial Overview
9.5.4 Recent Developments
9.6 Novartis
9.6.1 Company Overview
9.6.2 Product/Service Landscape
9.6.3 Financial Overview
9.6.4 Recent Developments
9.7 Takara Bio
9.7.1 Company Overview
9.7.2 Product/Service Landscape
9.7.3 Financial Overview
9.7.4 Recent Developments
9.8 Unum Therapeutics
9.8.1 Company Overview
9.8.2 Product/Service Landscape
9.8.3 Financial Overview
9.8.4 Recent Developments
The T-Cell Immunotherapy Market has been segmented as below:
T-Cell Immunotherapy Market, By Application
T-Cell Immunotherapy Market, By Type
T-Cell Immunotherapy Market, By Region
T-Cell Immunotherapy Market, By Company
SUBSCRIBE TO OUR NEWSLETTERS
